The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
![](https://cme.tarsusmedicaleducation.com/sites/default/files/styles/course_image_teaser/public/course/2024-05/Individualizing%20Treatment%20for%20Patients%20with%20Chronic%20Kidney%20050724.ai_1200x630.png?itok=P7wYqiSM)
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis.
Category
- CMHC
- TME
Format
- Self-study / Enduring
Credits
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation